Skip to main content
All lobbying filings

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed a Q1 report for Vertex Pharmaceuticals Incorporated on April 18, 2025.

Lobbying for Vertex Pharmaceuticals Incorporated

As filed: VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED.

All filings by Vertex Pharmaceuticals Incorporated · Everything Vertex Pharmaceuticals Incorporated has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 18, 2025
Expenses
$1,600,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Medicare/Medicaid

Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.

Taxation/Internal Revenue Code

Issues related to corporate tax reform.

Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.

Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem